Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22


The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.

Siedner MJ, Bwana MB, Moosa MS, Paul M, Pillay S, McCluskey S, Aturinda I, Ard K, Muyindike W, Moodley P, Brijkumar J, Rautenberg T, George G, Johnson B, Gandhi RT, Sunpath H, Marconi VC.

HIV Clin Trials. 2017 Jul;18(4):149-155. doi: 10.1080/15284336.2017.1349028. Epub 2017 Jul 18.


Automated prediction of HIV drug resistance from genotype data.

Shen C, Yu X, Harrison RW, Weber IT.

BMC Bioinformatics. 2016 Aug 31;17 Suppl 8:278. doi: 10.1186/s12859-016-1114-6.


Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1.

Banks L, Gholamin S, White E, Zijenah L, Katzenstein DA.

J AIDS Clin Res. 2012 Feb;3(2):141-147.


Clinical management of HIV drug resistance.

Cortez KJ, Maldarelli F.

Viruses. 2011 Apr;3(4):347-78. doi: 10.3390/v3040347. Epub 2011 Apr 14. Review.


Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa.

Maskew M, Brennan AT, MacPhail AP, Sanne IM, Fox MP.

J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb;11(1):57-65. doi: 10.1177/1545109711421641. Epub 2011 Sep 27.


The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention.

Hong SY, Nachega JB, Kelley K, Bertagnolio S, Marconi VC, Jordan MR.

Infect Disord Drug Targets. 2011 Apr;11(2):124-33. Review.


Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.

Fehr J, Glass TR, Louvel S, Hamy F, Hirsch HH, von Wyl V, Böni J, Yerly S, Bürgisser P, Cavassini M, Fux CA, Hirschel B, Vernazza P, Martinetti G, Bernasconi E, Günthard HF, Battegay M, Bucher HC, Klimkait T; Swiss HIV Cohort Study.

J Transl Med. 2011 Jan 21;9:14. doi: 10.1186/1479-5876-9-14.


Antiretroviral genotypic resistance mutations in HIV-1 infected Korean patients with virologic failure.

Chin BS, Choi JY, Choi JY, Kim GJ, Kee MK, Kim JM, Kim SS.

J Korean Med Sci. 2009 Dec;24(6):1031-7. doi: 10.3346/jkms.2009.24.6.1031. Epub 2009 Nov 7.


Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.

Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, Huebner RE, Janoff EN, Justice AC, Kuritzkes D, Nayfield SG, Plaeger SF, Schmader KE, Ashworth JR, Campanelli C, Clayton CP, Rada B, Woolard NF, High KP.

Clin Infect Dis. 2008 Aug 15;47(4):542-53. doi: 10.1086/590150.


Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.

Paredes R, Marconi VC, Campbell TB, Kuritzkes DR.

J Virol Methods. 2007 Dec;146(1-2):136-46. Epub 2007 Jul 26.


Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs.

Chiba-Mizutani T, Miura H, Matsuda M, Matsuda Z, Yokomaku Y, Miyauchi K, Nishizawa M, Yamamoto N, Sugiura W.

J Clin Microbiol. 2007 Feb;45(2):477-87. Epub 2006 Dec 20.


The pharmacology of HIV drug resistance.

Zdanowicz MM.

Am J Pharm Educ. 2006 Oct 15;70(5):100.


Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent.

Snoeck J, Kantor R, Shafer RW, Van Laethem K, Deforche K, Carvalho AP, Wynhoven B, Soares MA, Cane P, Clarke J, Pillay C, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas MB, Brun-Vézinet F, Reid C, Cahn P, Brigido LF, Grossman Z, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan RP, Camacho R, Schapiro JM, Katzenstein D, Vandamme AM.

Antimicrob Agents Chemother. 2006 Feb;50(2):694-701.


Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.

Martinez-Picado J, Wrin T, Frost SD, Clotet B, Ruiz L, Brown AJ, Petropoulos CJ, Parkin NT.

J Virol. 2005 May;79(10):5907-13.


Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma.

Ellis GM, Mahalanabis M, Beck IA, Pepper G, Wright A, Hamilton S, Holte S, Naugler WE, Pawluk DM, Li CC, Frenkel LM.

J Clin Microbiol. 2004 Aug;42(8):3670-4.


Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.

Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ.

Antimicrob Agents Chemother. 2004 Feb;48(2):437-43.


Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.

Shenderovich MD, Kagan RM, Heseltine PN, Ramnarayan K.

Protein Sci. 2003 Aug;12(8):1706-18.


Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System.

Kuritzkes DR, Grant RM, Feorino P, Griswold M, Hoover M, Young R, Day S, Lloyd RM Jr, Reid C, Morgan GF, Winslow DL.

J Clin Microbiol. 2003 Apr;41(4):1594-9.

Supplemental Content

Support Center